Biomea Fusion reports FY2025 net loss of $61.8M; cash runway into Q1 2027; initiates Phase II trials in diabetes

Biomea Fusion, Inc.

Net loss $61.8M for FY2025 vs $138.4M in FY2024; R&D expenses decreased 47% to $62.0M.
Cash and equivalents $56.2M as of Dec 31, 2025; projected cash runway into Q1 2027.
Initiated Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes; topline data expected Q4 2026.
Phase I trial GLP-131 (BMF-650) for obesity initiated; initial 28-day weight reduction data expected Q2 2026.
Positive 52-week data from COVALENT-111: 1.2% mean HbA1c reduction maintained 9 months off therapy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biomea Fusion, Inc. reported the year ended December 31, 2024 results: net income net loss of $138.4 million.

Period: the year ended December 31, 2024
Net income: net loss of $138.4 million
Result: reported results

Exact text from the filing

The Company reported a net loss attributable to common stockholders of $61.8 million for the year ended December 31, 2025, which included $9.5 million of stock-based compensation, compared to a net loss of $138.4 million for the same period in 2024, which included $19.1 million of stock-based compensation.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biomea Fusion, Inc. reported the full year ended December 31, 2025 results: net income net loss of $61.8 million.

Period: the full year ended December 31, 2025
Net income: net loss of $61.8 million
Result: reported results

Exact text from the filing

Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the full year ended December 31, 2025 and provided a business update.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Biomea Fusion, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-121811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.